Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis
Jiaqi Han, Kun Tian, Jianping Yang, Youling Gong
Topics & Concepts
DurvalumabMedicinePlaceboChemoradiotherapyLung cancerCost effectivenessOncologyInternal medicineCancerPathologyImmunotherapyRisk analysis (engineering)Alternative medicineNivolumabCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations